Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.
Soo Young JeongChel Hun ChoiTae Joong KimJeong Won LeeByoung-Gie KimDuk Soo BaeYoo Young LeePublished in: Journal of ovarian research (2019)
Delayed intervals to adjuvant chemotherapy after secondary cytoreductive surgery is not associated with decreased survivals. It is important to identify recurrent EOC patients who might have no gross residual disease following SCS. Moreover, surgeons should strive for complete resection.